title: European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma.
authors.affiliation: University of Bologna, Italy pierluigi.zinzani@unibo.it.
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.affiliation: Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
authors.forename: Lionel
authors.initials: L
authors.lastname: Karlin
authors.affiliation: University of Manchester and The Christie NHS Foundation Trust, UK.
authors.forename: John
authors.initials: J
authors.lastname: Radford
authors.affiliation: Hospital Universitario de Salamanca, Spain.
authors.forename: Dolores
authors.initials: D
authors.lastname: Caballero
authors.affiliation: Guy's Hospital, London, UK.
authors.forename: Paul
authors.initials: P
authors.lastname: Fields
authors.affiliation: Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands.
authors.forename: Martine E D
authors.initials: ME
authors.lastname: Chamuleau
authors.affiliation: Aarhus University Hospital, Denmark.
authors.forename: Francesco
authors.initials: F
authors.lastname: d'Amore
authors.affiliation: Hôpital Henri Mondor, Créteil, France.
authors.forename: Corinne
authors.initials: C
authors.lastname: Haioun
authors.affiliation: Hôpital Saint Louis, Paris, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Thieblemont
authors.affiliation: Institut Català d'Oncologia, Barcelona, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: González-Barca
authors.affiliation: Hospital Universitario 12 de Octubre, Madrid, Spain.
authors.forename: Carlos Grande
authors.initials: CG
authors.lastname: García
authors.affiliation: NIHR/CRUK Experimental Cancer Medicine Centre, University of Southampton, UK.
authors.forename: Peter W
authors.initials: PW
authors.lastname: Johnson
authors.affiliation: University Medical Center Groningen, University of Groningen, The Netherlands.
authors.forename: Gustaaf W
authors.initials: GW
authors.lastname: van Imhoff
authors.affiliation: Kyowa Kirin Pharmaceutical Development, Inc., Galashiels, Scotland.
authors.forename: Thomas
authors.initials: T
authors.lastname: Ng
authors.affiliation: Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ, USA.
authors.forename: Karen
authors.initials: K
authors.lastname: Dwyer
authors.affiliation: Unité GRITA, Université de Lille 2, France.
authors.forename: Franck
authors.initials: F
authors.lastname: Morschhauser
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D054398:Receptors, CCR4 / Q000037:antagonists & inhibitors*; D015996:Survival Rate / Q000639:trends; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C515354:CCR4 protein, human; D054398:Receptors, CCR4; C549035:mogamulizumab
keywords: aggressive non-Hodgkin lymphoma; anti-CCR4 monoclonal antibody; mogamulizumab; peripheral T-cell lymphoma